ストックスクリーナーアプリを入手
12.67
1.63%
-0.20
前日終値:
$12.87
開ける：
$12.66
24時間の取引高:
1.07M
Relative Volume:
0.41
時価総額：
$1.31B
収益：
$133.67M
当期純損益:
$-151.76M
株価収益率:
-8.5297
EPS:
-1.4854
ネットキャッシュフロー:
$-124.86M
1週間 パフォーマンス:
+18.87%
1か月 パフォーマンス:
+20.80%
6か月 パフォーマンス:
+67.68%
1年 パフォーマンス:
+30.52%
1日の値動き範囲:
$12.56
$13.11
1週間の範囲:
$9.97
$13.11
52週間の値動き範囲:
$5.635
$13.20
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
名前
Day One Biopharmaceuticals Inc
セクター
電話
650 484-0899
住所
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
12.68 | 1.33B | 133.67M | -151.76M | -124.86M | -1.4854 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.85 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.18 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.05 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.07 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.18 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | 再開されました | TD Cowen | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2024-10-09 | 繰り返されました | Needham | Buy |
| 2024-08-01 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-04-24 | 繰り返されました | Needham | Buy |
| 2023-04-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-02-08 | 開始されました | CapitalOne | Overweight |
| 2023-02-03 | 開始されました | Oppenheimer | Perform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-12-05 | 開始されました | Goldman | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
すべてを表示
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
Why Day One Biopharmaceuticals (DAWN) Is Up 17.7% After Positive EU Opinion For OJEMDA Approval - simplywall.st
DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise - Stocktwits
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 26.2%What's Next? - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Competitors - Meyka
DAWN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Day One Highlights OJEMDA’s EMA Progress, Updates Strategy - TipRanks
Day One Biopharmaceuticals updates presentation after CHMP positive opinion for OJEMDA; 2026 revenue guidance $225–250M - TradingView
Surging OJEMDA sales and EU backing drive Day One (Nasdaq: DAWN) outlook - Stock Titan
Day One Weighs OJEMDA Momentum Against Expanded Oncology Pipeline Risks - Sahm
DAWN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead (NASDAQ:DAWN) - Seeking Alpha
Research Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to Hold at Zacks Research - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Stock Analysis: Exploring 113.62% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Day One Biopharmaceuticals (DAWN) Touts Narrower Q4 Loss Challenging Bearish Profitability Narratives - simplywall.st
Day One Biopharmaceuticals Reports Strong 2025 Financial Results and Growth Outlook - Intellectia AI
Day One Biopharmaceuticals (NASDAQ:DAWN) Announces Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
What Analysts Are Saying About Day One Biopharmaceutical Stock - Benzinga
Needham lowers Day One Biopharmaceuticals price target on costs - Investing.com Australia
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down After Earnings Miss - MarketBeat
Day One Q4 Net Loss Narrows As OJEMDA Sales Jump 82%; Reaffirms FY26 Guidance; Stock Down - Nasdaq
Wedbush Forecasts Strong Price Appreciation for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock - MarketBeat
Needham & Company LLC Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $17.00 - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $22.00 at HC Wainwright - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lowers Day One Biopharmaceuticals price target to $22 By Investing.com - Investing.com Australia
Day One Biopharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:DAWN) 2026-02-25 - Seeking Alpha
Day One Biopharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Day One Biopharmaceuticals earnings missed by $0.02, revenue topped estimates - Investing.com Australia
Day One Biopharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Day One Biopharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Day One Biopharmaceuticals Q4 Loss Narrows, Revenue Rises; Shares Drop After Hours - marketscreener.com
Day One Highlights Transformational 2025 and OJEMDA Growth - TipRanks
Day One Biopharmaceuticals beats revenue estimates By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals beats revenue estimates - Investing.com
Day One Bio (DAWN) Q4 2025 Earnings Transcript - The Globe and Mail
First Solar Q4 net sales reach $1.68 billion, analysts expected $1.56 billion - Bitget
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance - Bitget
Lucid Group's Q4 revenue was $522.7 million, exceeding analysts' expectations of $459.4 million. - Bitget
Day One Biopharma (NASDAQ: DAWN) grows OJEMDA franchise and ADC oncology pipeline - Stock Titan
Earnings Flash (DAWN) Day One Biopharmaceuticals, Inc. Reports Q4 Revenue $52.8M, vs. FactSet Est of $49.8M - marketscreener.com
Day One Reports Fourth Quarter and Full Year 2025 Financial - GlobeNewswire
First Week of October 16th Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Day One Biopharmaceuticals earnings up next after Mersana deal - Investing.com South Africa
Day One Biopharmaceuticals earnings up next after Mersana deal By Investing.com - Investing.com Australia
Day One Biopharmaceuticals Inc. (Day One) has officially disclosed its financial report for the fourth quarter and full year of fiscal 2025. - Bitget
Why (DAWN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Examining the Future: Day One Biopharmaceutical's Earnings Outlook - Benzinga
Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q4 2025 Result - GuruFocus
Day One Biopharmaceuticals Inc (DAWN) 財務データ
収益
当期純利益
現金流量
EPS
Day One Biopharmaceuticals Inc (DAWN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dubow Adam | Gen Counsel & Secretary |
Feb 17 '26 |
Sale |
11.60 |
6,395 |
74,188 |
72,694 |
| York Charles N II | COO and CFO |
Feb 17 '26 |
Sale |
11.60 |
6,065 |
70,359 |
312,025 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Feb 17 '26 |
Sale |
11.60 |
15,459 |
179,338 |
204,603 |
| VASCONCELLES MICHAEL | Head of Research and Dev. |
Feb 17 '26 |
Sale |
11.60 |
2,728 |
31,647 |
4,397 |
3.96%
大文字化:
|
ボリューム (24 時間):